Briefing: Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says
Strategic angle: Families report financial and treatment struggles after GSK's price increases on asthma inhalers.
Editorial Staff
1 min read
Updated 4 months ago
GSK replaced a popular inhaler with a higher-priced version.
Patients faced significant financial burdens.
Treatment accessibility became a major concern.